Follistatin Gene Therapy Trials: What Actually Happened
Follistatin-344 has no FDA-approved application for any indication, in gene therapy form or as an injectable peptide. It is not listed on the FDA's 503A bulk drug substances list for compounding. Anyone encountering "Follistatin-344" marketed as a research peptide should understand that the actual human clinical evidence base was built around a gene therapy product, delivered once, under an FDA-authorized investigational protocol with medical monitoring, not a repeat-injection vial.
What is follistatin-344, exactly, and why does the name show up in trial titles?
Follistatin exists in the body as two natural splice variants, one of 315 amino acids and one of 344 amino acids. The 344-form is the version researchers cloned into an AAV1 viral vector for the muscular dystrophy and myositis trials described below. That is where the "FS344" and "follistatin-344" naming in trial literature comes from. It does not mean those trials used an injectable peptide of that name. For background on the biology, see what follistatin-344 is and how it interacts with myostatin.
Which trials actually happened in humans?
Two published clinical studies, from the same research group, form the core of the human evidence:
Becker muscular dystrophy, phase 1/2a. Patients received intramuscular injections of an AAV1 vector carrying the follistatin-344 gene. The trial was designed primarily to assess safety and feasibility, with functional outcomes as secondary measures (Mendell et al., 2015). A related report on the same or overlapping cohort described improved ambulation, using measures like six-minute walk distance, in some treated patients (Mendell et al., 2015).
Sporadic inclusion body myositis (sIBM). The same gene therapy approach was tested in this distinct, treatment-resistant muscle disease, with the published report describing improved functional outcomes in treated patients (Mendell et al., 2017).
Both are small, early-phase, open-label studies. Neither is a large randomized controlled trial. That matters because open-label functional improvements in muscle disease are vulnerable to placebo response, natural variability in disease course, and small sample sizes exaggerating apparent effect size. The trials answer "can this be given safely and does it look promising enough to study further," not "does this work" in the way a phase 3 trial would establish.
What has only been shown in animals, not people?
Most of the follistatin literature is preclinical. That is not a criticism, it is how drug development normally proceeds, but conflating mouse data with human evidence is the single most common distortion in how follistatin gets marketed online. Animal-only findings include:
- Follistatin overexpression improving myoblast transplant success in dystrophic mice (2008; 2009)
- Systemic follistatin aiding muscle repair in a Pompe disease mouse model (2010)
- Follistatin combined with micro-dystrophin gene delivery restoring function in an aged DMD mouse model (2013)
- Plasmid- and DNA-mediated follistatin gene therapy in limb girdle muscular dystrophy 2B mouse models (2017; 2019)
- AAV-delivered follistatin improving outcomes in a facioscapulohumeral muscular dystrophy (FSHD) mouse model (2018)
None of these have been replicated with human trial data at the time this article was written. For a broader accounting of what is and is not established across the whole evidence base, see follistatin evidence quality and muscle evidence in humans.
Why did myostatin-targeted approaches face headwinds in neuromuscular disease?
A 2017 analysis is worth reading on its own because it complicates the simple "block myostatin, grow muscle" narrative. The authors found that myostatin pathway signaling is already downregulated in several neuromuscular diseases, which may explain why anti-myostatin therapeutics, including follistatin-based approaches, have underperformed expectations in some disease contexts (Consalvi et al., 2017). Broader reviews of the muscular dystrophy gene therapy field echo this cautious framing: promising mechanism, uneven translation to durable clinical benefit (Mendell & Rodino-Klapac, 2012; Cossu, 2012). A 2025 review of dystrophin-restorative and compensatory gene therapies for Duchenne muscular dystrophy places follistatin approaches within a wider field now also considering newer tools like CRISPR activation, suggesting follistatin gene therapy has not become a standalone standard of care even within its own disease niche (2025).
Trial evidence vs. marketed peptide: a side-by-side reality check
| Feature | Published gene therapy trials | Online "Follistatin-344" peptide products |
|---|---|---|
| Delivery method | One-time AAV1 vector injection into muscle, under clinical protocol | Repeated subcutaneous or IM injection, self-administered |
| Population studied | Becker muscular dystrophy, sporadic IBM patients | None; no published trials of the injectable product |
| Regulatory status | Investigational, FDA-authorized trial protocol | No FDA approval for any use; not on the 503A bulks list |
| Monitoring | Clinical trial site, physician oversight, defined follow-up | None built in; user-managed |
| Sourcing and purity | Vector manufactured under trial-grade controls | Unregulated, purity and identity not independently verified |
| Outcome data | Small, open-label, early-phase signals; no phase 3 confirmation | No human outcome data exists |
The gap in the right-hand column is the point. Trial-grade evidence exists for a delivery method and patient population that has nothing to do with what is being sold as a general-purpose muscle-building peptide.
What should someone considering a follistatin peptide product actually weigh?
The honest answer is that the human trial data does not transfer to the injectable product being marketed. If muscle growth, recovery, or performance is the goal, that goal has evidence-backed comparators worth reading about first, including how follistatin claims stack up against creatine and general dosing claims scrutiny. If the interest is disease-specific, muscular dystrophy or IBM, that conversation belongs with a neuromuscular specialist who can discuss actual trial enrollment or approved standard-of-care options, not a self-sourced vial. Anyone with new or worsening muscle weakness, breathing difficulty, or swallowing problems should seek medical evaluation directly rather than attempting to self-treat with an unregulated product.
Where the evidence is established, plausible, and unproven
Established: AAV1-delivered follistatin-344 gene therapy has been tested in small human phase 1/2a trials for Becker MD and sporadic IBM, with safety data and some functional signal reported by the investigators.
Plausible but unproven: that these early signals would replicate in a larger controlled trial, or that follistatin gene therapy meaningfully changes long-term disease course.
Not established: any human safety or efficacy data for injectable, non-gene-therapy "Follistatin-344" peptide products; any benefit in healthy adults seeking muscle growth or athletic performance; FDA approval or legal compounding status of Follistatin-344 in any form. Check current regulatory status on the FDA Peptide Status Tracker, and review known risks before considering any use at follistatin side effects and risks.